Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Pembrolizumab for MMR-Deficient and EBV-Positive Gastric Cancer
NCT03257163Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Sep 2017
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastric adenocarcinoma, sponsored by Rutgers University. Primary endpoints: Recurrence-free survival rate at 3 years and Disease-free survival. Started Sep 2017; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03257163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257163.